Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study
This large real-world study confirms pembrolizumab's effectiveness and manageable safety profile in the adjuvant setting for intermediate-high and high-risk ccRCC. Further research is needed to refine patient selection strategies and evaluate long-term outcomes.
Authors
- Maria Teresa Bourlon (ORCID: https://orcid.org/0000-0002-3116-912X)
- Ondřej Fiala (ORCID: https://orcid.org/0000-0002-4096-7385)
- Zin Myint (ORCID: https://orcid.org/0000-0002-3479-4203)
- Umut Akova (ORCID: https://orcid.org/0000-0002-1768-0503)
- Sebastiano Buti (ORCID: https://orcid.org/0000-0003-0876-0226)
- Camillo Porta (ORCID: https://orcid.org/0000-0003-2412-1563)
- Matteo Santoni (ORCID: https://orcid.org/0000-0001-7340-6173)
- Thomas Büttner (ORCID: https://orcid.org/0000-0003-0316-9621)
- Jakub Kucharz (ORCID: https://orcid.org/0000-0001-5388-8910)
- Hatice Bölek (ORCID: https://orcid.org/0000-0001-8659-7327)
- Luca Galli (ORCID: https://orcid.org/0000-0001-6008-0266)
- Andrey Soares (ORCID: https://orcid.org/0000-0003-4980-6729)
- Ahmet Yildirim (ORCID: https://orcid.org/0009-0006-2542-3714)
- Veronica Mollica (ORCID: https://orcid.org/0000-0002-5169-3631)
- Giandomenico Roviello (ORCID: https://orcid.org/0000-0001-5504-8237)
- Enrique Grande (ORCID: https://orcid.org/0000-0002-0134-4732)
- Vincenza Conteduca (ORCID: https://orcid.org/0000-0002-6921-714X)
- Javier Molina‐Cerrillo (ORCID: https://orcid.org/0000-0003-4616-0598)
- Mimma Rizzo (ORCID: https://orcid.org/0000-0001-7743-741X)
- Jindřich Kopecký (ORCID: https://orcid.org/0000-0002-4126-0410)
- Ray Manneh Kopp (ORCID: https://orcid.org/0000-0002-8106-9741)
- Francesco Massari (ORCID: https://orcid.org/0000-0001-6476-6871)
- Yüksel Ürün (ORCID: https://orcid.org/0000-0002-9152-9887)
- Fernando Sabino Marques Monteiro (ORCID: https://orcid.org/0000-0002-6621-8251)
- Anca Florina Zgura (ORCID: https://orcid.org/0000-0002-2370-5762)
- Renate Pichler (ORCID: https://orcid.org/0000-0001-5286-9048)
- Matteo Rosellini (ORCID: https://orcid.org/0000-0002-4920-9951)
- Umberto Basso (ORCID: https://orcid.org/0000-0002-5075-2177)
- Tomáš Büchler (ORCID: https://orcid.org/0000-0001-6667-994X)
- Álvaro Pinto (ORCID: https://orcid.org/0000-0002-4719-053X)
- Alessandro Rizzo (ORCID: https://orcid.org/0000-0002-6085-648X)
- Mehmet Asim Bilen
- Haoran Li (ORCID: https://orcid.org/0000-0002-8485-9378)
- Timothy Schieber
- Antonia Partl
Institutions
- University of Foggia (IT)
- University of Parma (IT)
- Innsbruck Medical University (AT)
- Ankara University (TR)
- Emory University (US)
- Carol Davila University of Medicine and Pharmacy (RO)
- Universität Innsbruck (AT)
- Charles University (CZ)
- University Hospital Bonn (DE)
- Hospital Israelita Albert Einstein (BR)
- Hospital Universitario La Paz (ES)
- Markey Cancer Center (US)
- Westwood College (US)
- Popular University of Cesar (CO)
- Ospedali Riuniti di Foggia (IT)
- Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari (IT)
- The University of Kansas Cancer Center (US)
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (MX)
- University Hospital in Motol (CZ)
- Istituto Oncologico Veneto (IT)
- Azienda USL di Bologna (IT)
- Institutul Oncologic Bucuresti (RO)
- Istituto Tumori Bari (IT)
- University Hospital Hradec Králové (CZ)
- Hospital Sírio-Libanês (BR)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- MD Anderson Cancer Center Madrid (ES)
- Hospital Universitario Ramón y Cajal (ES)
- Azienda Ospedaliera Universitaria Pisana (IT)
- Ospedale di Macerata
- University of Florence (IT)
- University of Macerata (IT)
- University of Bari Aldo Moro (IT)
- University of Bologna (IT)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2025-11-14
- DOI
- https://doi.org/10.1007/s00262-025-04230-w
- Citations
- 1
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.52